Our mission is to disrupt the field of surgery and positively impact the lives of patients through the development of our platform of biomorphic programmable polymers
TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function.
Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas.
Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices.
We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.
Meet our leadership team
Co-Founder, Chief Executive Officer
Christophe Bancel is Co-founder and CEO of TISSIUM. Prior to founding the company, he has held corporate and strategic leadership positions at UCB and Serono and was Co-founder and Business Development Director at Domain Therapeutics. Christophe holds a MSc in Engineering from Ecole Centrale Paris, a MSc in Molecular Biology from the University of Tokyo, and an MBA from INSEAD.
Maria Pereira leads the Innovation Hub at TISSIUM. She co-invented the technology while a PhD student at Prof. Jeff Karp’s Laboratories. She has been recognized for her research by MIT Tech Review’s “35 Innovators Under 35” in 2014, as well as Forbes in its “30 under 30” selection in Healthcare in 2015. Maria holds a PhD in Bioengineering from the MIT-Portugal program and an MBA from INSEAD.
Hunt Henrie joined Tissium in early 2021. He is an experienced financial, strategic and biomedical executive with over 30 years of broad-based global financial, investment banking, private equity and corporate C-Level operating experience in public and private healthcare companies. Before joining Tissium Hunt created Sachuest Partners, a strategic advisory firm focused on building leading MedTech companies
Thierry Darnis leads the Global Operations at Tissium, (Development & industrialization, Quality, Chemical Characterization and Manufacturing). He has a deep background of more than 30 years as a global leader managing major medical device design and production units at world-class companies such as Medtronic and CR Bard but also at innovative startups. Thierry holds a PhD in Biology and Health, specializing in Biomaterials from the University of Bordeaux II.
Romain is CFO of Tissium. Prior to joining Tissium, Romain spent 11 years working in Corporate Finance at ODDO BHF. Most recently, he served as Managing Director and head of Public M&A / ECM France. He supported numerous IPOs as well as capital increases, delistings, takeovers and other M&A transactions. Romain holds a MSc in Engineering from Ecole Centrale Lille, a Master in Strategy & Management of International Business from ESSEC Business School and did an exchange program at Thunderbird School of Global Management.
Ruth Krestin is the VP of Portfolio Strategy at Tissium. Ruth has over 11 years of experience in the pharma industry. After starting her career in strategy consulting at PwC, Ruth most recently spent 6 years at AstraZeneca, holding roles of increasing responsibility in both R&D and commercial, including portfolio management, business insights and competitive intelligence. Ruth holds a MSc in Technology Policy from MIT and a BSc in Life Science from University College Utrecht.
Alex Milstein is the Chief Medical Officer at Tissium. Alex has over 20 years of experience in the medical device industry. Throughout his career, he has gained extensive international leadership experience in the US, Canada, Latin America, as well as Europe, the Middle East, and Asia. He has worked in the fields of medical devices, stem cell therapies, drug device combinations, and biotechnology products. Alex holds a medical degree from The Russian State Medical University and completed a research fellowship in medicine at Harvard University.
Thierry Proust joined Tissium early 2023 and is in charge of Human Resources. Thierry has more than 25 years of experience in the Biotech and Pharma industry mainly at Guerbet, Roche and UCB. He led different HR teams at affiliates, manufacturing sites, and Global organizations. Today, he supports the development of TISSIUM HR infrastructure globally, with a focus on recruitment and people development.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.